Status:
UNKNOWN
The Function of PET Molecular Imaging Targeting Fibroblast Activation Protein in the Hepatobiliary Malignancies
Lead Sponsor:
Zhongnan Hospital
Conditions:
Hepatobiliary Diseases
Eligibility:
All Genders
18-80 years
Brief Summary
Patients with high clinical suspicion of hepatobiliary malignancies should undergo PET/CT examination with two imaging agents, 68Ga-FAPI (fibroblast activation protein inhibitor) and 18F-FDG within on...
Detailed Description
Patients with high clinical suspicion of hepatobiliary malignancies should undergo PET/CT examination with two imaging agents, 68Ga-FAPI (fibroblast activation protein inhibitor) and 18F-FDG within on...
Eligibility Criteria
Inclusion
- Voluntarily participate and sign a written informed consent;
- 18-80 years old (inclusive) male or female;
- Patients with high clinical suspicion of hepatobiliary malignancy in combination with medical history and imaging studies, etc.
- Those who obtained pathological diagnosis results through needle biopsy or surgical resection;
- Have willingness and ability to participate in all research procedures.
Exclusion
- Women who are pregnant or breastfeeding;
- Those who are known to be allergic to the imaging agent 68Ga-FAPI or its excipients;
- Those who have a history of other malignant tumors in the past;
- Before the injection of 18F-FDG, the fasting blood glucose level exceeds 11.0mmol/L;
- Patients with claustrophobia;
- Those who cannot tolerate lying down for 15-30 minutes;
- The researchers believe that it is not suitable to participate in this clinical trial;
- Those who have participated in clinical trials or are participating in other clinical trials within the past month
Key Trial Info
Start Date :
January 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05264688
Start Date
January 20 2022
End Date
October 31 2022
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital
Wuhan, Hubei, China, 430000